Posters

POSTER SUBMISSION GUIDELINES

Virtual poster sessions offer the opportunity to present data to a global audience via a PDF poster and video summary, and discuss results with interested colleagues through email. Posters should be submitted as a PowerPoint file. Presentations should incorporate illustrative materials such as tables, graphs, photographs, and large-print text. This content is not peer reviewed. Submission is free.

SUBMIT YOUR ABSTRACT

Enter the following information to this Submission Form:

  • Poster Title
  • Your Name
  • Your Institution
  • Your Email
  • Abstract describing the poster

All submitted abstracts will be reviewed and decisions regarding acceptance will be made as abstracts are received. You will be notified within one week of receipt about acceptance. Further details and registration materials will be provided at that time. You do not have to be present in order to have a poster displayed. Only those abstracts approved by LabRoots may display posters at this event.

If accepted, you will also have the opportunity to record a 3-5 minute summary video for each poster. LabRoots will work with each individual to create these videos. Video links and email contact information will be included on each poster displayed.

Questions? Email Posters@LabRoots.com

LabRoots Policy

OCT 10 - 11 2018

Cancer Research & Oncology 2018

 

 

Our 6th Annual Cancer Research & Oncology Virtual Event is now available On Demand!

This free online event will bring research professionals, scientists, and clinicians from around the world to learn and discuss recent advances in cancer research. As with all LabRoots events, the Cancer Research and Oncology Event encourages a worldwide collaboration and connections between colleagues and field experts.

Cancer research has made major advancements in diagnosis, treatments, and the basic understanding of the disease itself. Each year we see progress in immunotherapy, treatments involving nanotechnology, advances in targeted and personalized therapeutics and drug development, and a decrease in mortality rates due to a strong focus on learning more about the origination of the disease.


Topic's for this years event included:

  • Cancer Therapeutics and Vaccines
  • Cancer Epigenetics and Natural History
  • Cancer Microbiome
  • Cancer Diagnostics
     

Our virtual conference allows you to participate in a global setting with no travel or cost to you. You can participate in exactly those parts which you are interested in and be back at your desk or bench in an instant. Virtual events remove time and place restrictions and ensure that everyone who wants to participate can do so. This virtual conference also offers increased reach for the global cancer community with a high degree of interaction through live-streaming video and chat sessions.


Call for Speakers —  We are always looking to feature excellent research during our virtual events. If you’re working on some remarkable breakthroughs and would like to submit a speaker or panel for consideration, please submit your abstract here.

Don't forget to participate in our Leaderboard and Scavenger Hunt to win one of our Free Science T-shirts!  

Continuing Education
By participating in this virtual event and watching webcast presentations, you can earn Free Continuing Education (PACE). To earn educational credits, you must view an entire presentation. Following the presentation, you must click on the educational credit link provided for that particular speaker and follow the required process. Once you have completed the process, you will receive a certificate for the educational credit.

Use #LRcancer to follow the conversation!


Speakers

Show Resources
You May Also Like
SEP 14, 2016 06:30 AM PDT
C.E. CREDITS
SEP 14, 2016 06:30 AM PDT
An industry leader in delivering instrument systems, reagents, and services to life science researchers,Beckman Coulter Life Sciences helps enable new discoveries in biology-based research...
NOV 02, 2016 06:00 AM PDT
C.E. CREDITS
NOV 02, 2016 06:00 AM PDT
The 7th annual Clinical Diagnostics & Research conference is now On Demand!  This premiere venue discusses the latest advances in clinical diagnostics, research and medicine. The con...
NOV 08, 2017 06:00 AM PST
C.E. CREDITS
NOV 08, 2017 06:00 AM PST
LabRoots invites you to the 8th annual Clinical Diagnostics & Research free online conference! Clinical diagnostics is an ever-changing field of medicine and research, challenged wit...
NOV 11, 2015 06:00 AM PST
C.E. CREDITS
NOV 11, 2015 06:00 AM PST
Welcome to LabRoots’ 6th Annual Clinical Diagnostics & Research free online conference! The event is now available on-demand and you can attend sessions including keynotes...
MAY 28, 2014 06:00 AM PDT
C.E. CREDITS
MAY 28, 2014 06:00 AM PDT
This year will be our 5th annual Clinical Diagnostics & Research online conference. Attendees can earn free CME and CE Credits. The theme of this conference is a range of medical and clin...
OCT 16, 2013 06:00 AM PDT
C.E. CREDITS
OCT 16, 2013 06:00 AM PDT
BioConference Live makes it easier and more cost-effective for the cancer research community to come together online through live video webcasts and real-time networking. BioConference Live a...
Agenda
  • OCT 10, 2018 06:00 AM PDT
    Precise Detection of T-Cell Receptors Using RNAseq With Unique Molecular Indexing
    Speaker: Samuel Rulli, PhD
    Sponsored By: QIAGEN
  • OCT 10, 2018 06:00 AM PDT
    The Role of Vaccination for the Treatment and Prevention of Breast and Ovarian Cancers
    Speaker: Keith Knutson, PhD
  • OCT 10, 2018 07:30 AM PDT
    Keynote Presentation: Proteogenomics and Cancer Biology: Insights for Prognosis and Therapy
    Speaker: Karin Rodland, PhD
  • OCT 10, 2018 09:00 AM PDT
    Understanding Cancer Through Whole-Genome Screening
    Speaker: Andrew Ravanelli, PhD
    Sponsored By: MilliporeSigma
  • OCT 10, 2018 09:00 AM PDT
    Using Radiotherapy, Tumor-Reactive mAb and IL2 to Engage Innate and Adaptive Antitumor Immunity
    Speaker: Paul Sondel, MD, PhD
  • OCT 10, 2018 10:30 AM PDT
    Metabolic Networks in the Tumor Microenvironment
    Speaker: Costas A. Lyssiotis, PhD
    Sponsored By: Agilent
  • OCT 10, 2018 10:30 AM PDT
    Microbiome Signatures in Gynecologic Cancers
    Speaker: Marina Walther-Antonio, PhD
  • OCT 10, 2018 12:00 PM PDT
    Integrative Cancer Immunology and Novel Concepts of Cancer Evolution
    Speaker: Jerome Galon, PhD
  • OCT 10, 2018 12:00 PM PDT
    Sample to Insight: Everything You Need to Know About RNA Sequencing
    Speaker: Jonathan Shaffer, PhD
    Sponsored By: QIAGEN
  • OCT 10, 2018 01:30 PM PDT
    Speaker: Benjamin Haibe-Kains, PhD
  • OCT 11, 2018 06:00 AM PDT
    Revealing the Hidden Landscape of Structural Variants in Cancer Genomes
    Speaker: Jonas Korlach, PhD
  • OCT 11, 2018 07:30 AM PDT
    Keynote Presentation: In Advanced Cancers Curative Therapies Must Target All Cancer Cells
    Speaker: Krastan Blagoev, PhD
  • OCT 11, 2018 09:00 AM PDT
    Destabilization and Degradation of MYC: More Ways Than One
    Speaker: Jason De Melo, PhD
  • OCT 11, 2018 09:00 AM PDT
    Discovering Cellular Mechanisms and Markers in Anti-PD1 Non-Responders Through Ingenuity Pathway Analysis and Oncoland
    Speaker: Devendra Mistry, PhD
    Sponsored By: QIAGEN
  • OCT 11, 2018 10:30 AM PDT
    Drug Targeting for Inflammatory Breast Cancer
    Speaker: Kevin Williams, PhD
  • OCT 11, 2018 10:30 AM PDT
    Validating and Publishing with Antibodies- How to Avoid Reviewer's Challenges
    Speaker: Chandra Mohan, PhD
    Sponsored By: MilliporeSigma
  • OCT 11, 2018 12:00 PM PDT
    Aurora Kinase A Drives The Evolution of Resistance to Third Generation EGFR Inhibitors in Lung Cancer
    Speaker: Khyati Shah, PhD
  • OCT 11, 2018 12:00 PM PDT
    Lung Cancer Evolution and Immune Escape
    Speaker: Nicholas McGranahan, PhD
  • OCT 11, 2018 01:30 PM PDT
    Breast Cancer as a Global Disease: Are We Up to The Challenge?
    Speaker: Benjamin Anderson, MD
  • OCT 11, 2018 01:30 PM PDT
    Exploiting Cis-Regulatory Enhancers as Therapeutic Targets in Cancer
    Speaker: Martin Hirst, PhD
  • Cancer Diagnostics
  • OCT 10, 2018 06:00 AM PDT
    Precise Detection of T-Cell Receptors Using RNAseq With Unique Molecular Indexing
    Speaker: Samuel Rulli, PhD
    Sponsored By: QIAGEN
  • OCT 10, 2018 07:30 AM PDT
    Keynote Presentation: Proteogenomics and Cancer Biology: Insights for Prognosis and Therapy
    Speaker: Karin Rodland, PhD
  • OCT 10, 2018 09:00 AM PDT
    Understanding Cancer Through Whole-Genome Screening
    Speaker: Andrew Ravanelli, PhD
    Sponsored By: MilliporeSigma
  • OCT 10, 2018 12:00 PM PDT
    Sample to Insight: Everything You Need to Know About RNA Sequencing
    Speaker: Jonathan Shaffer, PhD
    Sponsored By: QIAGEN
  • OCT 10, 2018 01:30 PM PDT
    Speaker: Benjamin Haibe-Kains, PhD
  • OCT 11, 2018 06:00 AM PDT
    Revealing the Hidden Landscape of Structural Variants in Cancer Genomes
    Speaker: Jonas Korlach, PhD
  • OCT 11, 2018 09:00 AM PDT
    Discovering Cellular Mechanisms and Markers in Anti-PD1 Non-Responders Through Ingenuity Pathway Analysis and Oncoland
    Speaker: Devendra Mistry, PhD
    Sponsored By: QIAGEN
  • OCT 11, 2018 10:30 AM PDT
    Validating and Publishing with Antibodies- How to Avoid Reviewer's Challenges
    Speaker: Chandra Mohan, PhD
    Sponsored By: MilliporeSigma
  • Cancer Therapeutics and Vaccines
  • OCT 10, 2018 06:00 AM PDT
    The Role of Vaccination for the Treatment and Prevention of Breast and Ovarian Cancers
    Speaker: Keith Knutson, PhD
  • OCT 10, 2018 09:00 AM PDT
    Using Radiotherapy, Tumor-Reactive mAb and IL2 to Engage Innate and Adaptive Antitumor Immunity
    Speaker: Paul Sondel, MD, PhD
  • OCT 10, 2018 12:00 PM PDT
    Integrative Cancer Immunology and Novel Concepts of Cancer Evolution
    Speaker: Jerome Galon, PhD
  • OCT 11, 2018 10:30 AM PDT
    Drug Targeting for Inflammatory Breast Cancer
    Speaker: Kevin Williams, PhD
  • OCT 11, 2018 12:00 PM PDT
    Aurora Kinase A Drives The Evolution of Resistance to Third Generation EGFR Inhibitors in Lung Cancer
    Speaker: Khyati Shah, PhD
  • OCT 11, 2018 01:30 PM PDT
    Breast Cancer as a Global Disease: Are We Up to The Challenge?
    Speaker: Benjamin Anderson, MD
  • Cancer Epigenetics and Natural History
  • OCT 10, 2018 10:30 AM PDT
    Metabolic Networks in the Tumor Microenvironment
    Speaker: Costas A. Lyssiotis, PhD
    Sponsored By: Agilent
  • OCT 11, 2018 07:30 AM PDT
    Keynote Presentation: In Advanced Cancers Curative Therapies Must Target All Cancer Cells
    Speaker: Krastan Blagoev, PhD
  • OCT 11, 2018 09:00 AM PDT
    Destabilization and Degradation of MYC: More Ways Than One
    Speaker: Jason De Melo, PhD
  • OCT 11, 2018 12:00 PM PDT
    Lung Cancer Evolution and Immune Escape
    Speaker: Nicholas McGranahan, PhD
  • OCT 11, 2018 01:30 PM PDT
    Exploiting Cis-Regulatory Enhancers as Therapeutic Targets in Cancer
    Speaker: Martin Hirst, PhD
  • Cancer Microbiome
  • OCT 10, 2018 10:30 AM PDT
    Microbiome Signatures in Gynecologic Cancers
    Speaker: Marina Walther-Antonio, PhD
Speakers

CALL FOR SPEAKERS: We are always looking to feature excellent research during our virtual events. If you’re working on some remarkable breakthroughs and would like to submit a speaker or panel for consideration, please submit your abstract here.


  • Karin Rodland, PhD
    Director and Professor, Biological Sciences Division, Pacific Northwest National Laboratory
    Biography
      Dr. Karin Rodland joined the Biological Sciences Division at the Pacific Northwest National Laboratory in October 2001, after serving seventeen years on the faculty of Oregon Health Sciences University. As Chief Scientist for Biomedical Research at PNNL, she has promoted the application of PNNL's traditional strengths in mass spectrometry, proteomics, and systems biology to important problems in biomedical research. She is currently the PNNL co-Director of the OHSU-PNNL Precision Medicine Innovation CoLaboratory, a joint effort dedicated to improving patient outcomes through the integration of cutting edge technologies in integrated omics, imaging, and data analysis to advance the goals of precision medicine. Dr. Rodland's own research focuses on signal transduction pathways that regulate proliferation in normal and malignant cells. She was the first to recognize the role of the calcium-sensing receptor in modulating proliferation in response to small molecules in the extracellular environment. Since joining PNNL, she has adopted a systems biology approach to signal transduction and has become a recognized expert in the field of proteomics and cancer biomarkers. She is a full member of the National Cancer Institute's Early Detection Research Network, and is the chair of the Clinical Proteomics Tumor Analysis Consortium Steering Committee. She has served as Chair of the Cancer Biomarkers Study Section for the NIH, as well as the Department of Defense Congressionally Directed Medical Research Program Integration Panels for both Ovarian and Breast Cancer Research.
    • Krastan Blagoev, PhD
      Program Director, National Science Foundation
      Biography
        Dr. Blagoev completed his first MS degree in Nuclear and Elementary Particle Physics at Sofia University in 1990 and a second MS degree at the Physics Department at Florida Atlantic University in 1992. He received a PhD from the Physics Department at Boston College in 1998 and continued his research on superconductivity and magnetism at University of Cambridge as a postdoctoral fellow. In 1999 he moved to Harvard University Medical School working on mathematical models of ultrasound propagation in the brain. In 2002 he joined the Theoretical Division of Los Alamos National Laboratory as a staff member working on condensed matter physics as well as mathematical models of telomere dynamics and its influence on aging and cancer. Dr. Blagoev moved to the National Science Foundation as a Program Director in the Division of Physics in 2007, where he currently directs the Physics of Living Systems program. Since 2015 he is an Associate Research Scientist at the Department of Biophysics at Johns Hopkins University. His research interests focus on understanding the mechanisms of tumor growth during cancer progression and analysis of cancer clinical trials. He is also interested in the non-equilibrium phyical processes in mammalian cells and their role in DNA repair.
      • Benjamin Anderson, MD
        Professor of Surgery, Division of General Surgery (Surgical Oncology Section), University of Washington School of Medicine
        Biography
          Dr. Anderson's is an internationally recognized leader in global cancer control. With joint appointments at the Fred Hutchinson Cancer Research Center Division of Public Health Sciences and the UW Department of Global Health, Dr. Anderson created in 2002 and continues to chair the Breast Health Global Initiative (BHGI), a unique program to develop "resource-stratified" guidelines for breast cancer early detection, diagnosis, treatment and palliative care in low- and middle-income countries (LMICs). In 2011 the American Society of Clinical Oncology (ASCO) awarded Dr. Anderson their Partners in Progress Award and in 2013 the National Consortium of Breast Centers (NCBC) awarded him their 2013 Inspiration Award, recognizing his dedicated efforts to improve the quality and effectiveness of breast cancer care around the globe. Since 2012, Dr. Anderson has served on the Board of Directors of the Union for International Cancer Control (UICC). Dr. Anderson now co-chairs the Breast Cancer Initiative 2.5 (BCI2.5), a global campaign to reduce disparities in breast cancer outcomes for 2.5 million women between now and 2025.
        • Jason De Melo, PhD
          Post-Doctoral Fellow, Princess Margaret Cancer Research, University Health Network
          Biography
            Dr. Jason De Melo is a post-doctoral fellow in the laboratory of Dr. Linda Penn at the Princess Margaret Cancer Centre in Toronto, Canada where his work focuses on elucidating a new degradation pathway for the MYC oncoprotein. Prior to his current position, Jason graduated from the University of Waterloo with a B.Sc in Biochemistry with a specialization in Biotechnology. His studies included work placements at Environment Canada, the Public Health Agency of Canada and Lorus Therapeutics. Jason then moved to McMaster University where he studied under the supervision of Dr. Damu Tang, graduating with a Ph.D. in Medical Sciences. Jason's work examined the role of SHARPIN in the regulation of the tumoursuppressor PTEN in Breast Cancer. In addition to his research work, Jason now teaches a course on Genome Editing at the Michener Institute for Education at UHN.
          • Jerome Galon, PhD
            Research Director, French Institute of Health and Medical Research
            Biography
              Dr. Jérôme Galon specialized in the fields of immunology and cancer, Jérôme Galon is Research Director at INSERM (French NIH), and head of the laboratory of Integrative Cancer Immunology, in Paris, France. He is associate Director and co-founder of European Academy of Tumor Immunology (EATI), board member of Society for Immunotherapy of Cancer (SITC). His work on the comprehensive analysis of the tumor-microenvironment and the role of T-cells in human cancer led to the demonstration of the importance of adaptive pre-existing immunity in human cancer, and the concept of cancer immune-contexture. He pioneered the Immunoscore. He is the co-founder of HalioDx company and the Chairman of its scientific council. His contributions have been recognized with numerous awards, including the William B. Coley Award, an international prize which honors the best scientists in the fundamental and cancer immunology, and Award from the National Academy of Science, and Award from the National Academy of Medicine.
            • Benjamin Haibe-Kains, PhD
              Assistant Professor, Princess Margaret Cancer Center, University of Toronto
              Biography
                Benjamin Haibe-Kains is a Scientist at the Princess Margaret Cancer Centre (PM), University Health Network, and Assistant Professor in the Medical Biophysics and Computer Science departments of the University of Toronto. Dr. Haibe-Kains earned his PhD in Bioinformatics at the Université Libre de Bruxelles (Belgium), for which he was awarded a Solvay Award (Belgium). Supported by a Fulbright Award, Dr. Haibe-Kains did his postdoctoral fellowship at the Dana-farber Cancer Institute and Harvard School of Public Health (USA). Dr. Haibe-Kains started his own laboratory at the Institut de Recherches Cliniques de Montréal (Canada) and moved to PM in November 2013. Dr. Haibe-Kains' research focuses on the integration of high-throughput data from various sources to simultaneously analyze multiple facets of carcinogenesis. Dr. Haibe-Kains and his team are analyzing high-throughput (pharmaco)genomic datasets to develop new prognostic and predictive models and to discover new therapeutic regimens in order to significantly improve disease management. Dr. Haibe-Kains' main scientific contributions include several prognostic gene signatures in breast cancer, subtype classification models for ovarian and breast cancers, as well as genomic predictors of drug response in cancer cell lines.
              • Martin Hirst, PhD
                Associate Professor, Associate Director, University of British Columbia
                Biography
                  Dr. Hirst is an Associate Professor in the Department of Microbiology and Immunology, Associate Director of the Michael Smith Laboratories at the University of British Columbia (UBC) and Head of Epigenomics at Canada's Michael Smith Genome Sciences Centre. Dr. Hirst was one of the first in the world to successfully complete ChIP-seq, RNA-seq and miRNA-seq experiments on the nascent Solexa 1G platform and for the last 10 years he has led the development of an internationally recognized epigenomic research program at UBC and BC Cancer. As a member of the NIH Human Reference Epigenomic Mapping Consortium, he led the development of epigenomic analysis tools for comprehensive molecular profiling of human tissues and cells. He currently leads the Centre of Epigenomic Mapping Technologies (CEMT) that represents one of two Canadian epigenomic mapping centres funded as part of the CIHR signature initiative; the Canadian Epigenetics, Environment and Health Research Consortium (CEEHRC). Dr. Hirst currently chairs the Scientific Steering Committee of the International Human Epigenome Consortium (IHEC; ihec.org) and leads the Canadian Epigenetics, Environment and Health Research Consortium Network (epigenomes.ca) with a mandate to drive epigenetic research in Canada and internationally. Dr. Hirst's research focuses on understanding the role of epigenetic deregulation in cancer. To enable tracking and epigenomic profiling of rare subsets of normal and transformed cell types he recently developed a genomic barcoding strategy, a native ChIP-seq protocol, and a PBAT methodology for profiling DNA methylation genome wide down to a single cell level. He has applied these and other tools to explore the epigenomic states of highly-purified and functionally defined normal and transformed cell types and is currently characterizing vitamin C induced epigenomic reprograming in leukemic models.
                • Keith Knutson, PhD
                  Professor of Immunology, Mayo Clinic
                  Biography
                    Keith L. Knutson, Ph.D., is a consultant in the Department of Immunology, Mayo Clinic in Florida, where he also serves as director of the Discovery and Translation Lab's Cancer Research Program. Dr. Knutson joined the staff of Mayo Clinic in 2005 and holds the academic rank of Professor of Immunology, Mayo Clinic College of Medicine and Science. Dr. Knutson is also Director of the Mayo Clinic Cancer Center's Cancer Immunology and Immunotherapy Program. Dr. Knutson received his B.S. in Microbiology at the University of Washington. He earned his Ph.D. in Physiology and Pharmacology from the University of Georgia and completed two postdoctoral fellowships in immunology, one at the University of British Columbia and the other at the University of Washington. Dr. Knutson is internationally recognized in the field of cancer immunology. His research focuses on the immunology and immunotherapy of breast and ovarian cancers, both the basic immunobiology and clinical translation, including clinical trials. His contributions to science include clinical development and testing of self-tumor antigen-specific vaccines in patients with breast and ovarian cancers. He currently has three FDA-approved vaccine trials underway and is principal investigator of 3 Department of Defense grants to test vaccines aimed at preventing recurrence breast cancer, including triple negative breast cancer for which there are no targeted therapies. Dr. Knutson is frequently invited to give presentations on his research both domestically and internationally, and he has authored numerous journal articles, abstracts and other written publications, consistently publishing in high-impact scientific journals. Additionally, he holds reviewer responsibilities for several prominent publications. In recognition of his work, Dr. Knutson has received many awards and honors, including the Young Investigator Award-Pharmingen, conferred by the American Association for Cancer Research, and the prestigious Howard Temin Award, conferred by the National Institutes of Health, National Cancer Institute. He is also recognized as the 2017 Investigator of the Year at the Mayo Clinic campus in Florida. In addition to his research activities, Dr. Knutson is active in education and has mentored postdoctoral fellows, research associates and medical students, among others. He holds full faculty privileges in Immunology in Mayo Clinic Graduate School of Biomedical Sciences. Dr. Knutson's has several current and past memberships with professional organizations which include the Breast Cancer Research Program and the Ovarian Cancer Research Program of the United States Department of Defense, the Tumor Microenvironment Study Section of the U.S. National Institutes of Health Center for Scientific Review, and the Education and Training Committee for the Society for the Immunotherapy of Cancer. He is a Principal Investigator of the Artemis Project, National Breast Cancer Coalition, where he is leading efforts to produce prevention vaccines for breast cancer.
                  • Jonas Korlach, PhD
                    Chief Scientific Officer, Pacific Biosciences
                    Biography
                      Jonas Korlach was appointed Chief Scientific Officer of Pacific Biosciences in July 2012. He was previously a Scientific Fellow, supporting commercial development of the PacBio RS II system and performing research aimed at developing new applications for SMRT technologies. He co-invented the SMRT technology with Stephen Turner, Ph.D., Pacific Biosciences Founder and Chief Technology Officer, when the two were graduate students at Cornell University. Dr. Korlach joined Pacific Biosciences as the company's eighth employee in 2004. Previously, he was a Postdoctoral Researcher at Cornell University. Dr. Korlach is the recipient of multiple grants, an inventor on 70 issued U.S. patents and 61 international patents, and an author of over 70 scientific studies on the principles and applications of SMRT technology, including publications in Nature, Science, and PNAS. In 2013, Dr. Korlach was honored by the Obama White House as an Immigrant Innovator "Champion of Change." He received both his Ph.D. and his M.S. degrees in Biochemistry, Molecular and Cell Biology from Cornell, and received M.S. and B.A. degrees in Biological Sciences from Humboldt University in Berlin, Germany.
                    • Costas A. Lyssiotis, PhD
                      Assistant Professor, Department of Molecular and Integrative Physiology, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Rogel Cancer Center, University of Mich
                      Biography
                        Costas A. Lyssiotis obtained his bachelor's degree in Chemistry and Biochemistry from the University of Michigan in 2004, his PhD in Chemical Biology from The Scripps Research Institute in 2010, and then completed postdoctoral training in the laboratory of Lewis C. Cantley at Harvard and Cornell. In 2015, Dr. Lyssiotis joined the faculty at the University of Michigan with appointments in the Departments of Physiology and Medicine. His lab studies the biochemical pathways and metabolic requirements that enable tumor survival and growth. This work spans the areas of cancer metabolism, the tumor microenvironment and immunometabolism using and developing protocols in mass spectrometry-based metabolomics. Ultimately, his group aims to transition new information about these processes into targeted therapies for cancer and other diseases. He is the recipient of several junior scholar awards including being named a Lefkofsky Scholar, a Kimmel Scholar, an AACR NextGen young investigator, a Dale F. Frey Breakthrough Scientist, and a V Foundation Fellow.
                      • Nicholas McGranahan, PhD
                        Senior Research Associate, Cancer Genome Evolution Research Group, University College London
                        Biography
                          Dr. Nicholas McGranahan completed his undergraduate degree in Natural Sciences, specializing in Evolutionary Genetics, at the University of Bath before pursuing post-graduate studies at University College London at the Centre of Mathematics and Physics in the Life Science and Experimental Biology (CoMPLEX). In 2011, Dr. McGranahan joined Professor Charles Swanton's group at the CR-UK London Research Institute (now the Francis Crick Institute), completing a PhD in Cancer Genomics in 2015. As a junior group leader and Sir Henry Dale Fellow within the CRUK Lung Cancer Centre of Excellence, Dr. McGranahan's research interests include using bioinformatics to dissect cancer genome evolution and the mechanisms of drug resistance, intra-tumour heterogeneity and genomic instability. His work involves exploring the evolutionary history of cancers through sequencing multiple regions of individual tumours. In particular, Dr. McGranahan's research has focused on understanding the importance of genome doubling in tumour evolution, as well as exploring the mutational processes shaping the genomes of cancers over space and time. Dr McGranahan has authored over 30 articles in high impact journals, including first author publications in New England Journal of Medicine, Science, Nature and Cell.
                        • Devendra Mistry, PhD
                          Senior Field Application Scientist, Bioinformatics, QIAGEN
                          Biography
                            Devendra (Dev) received his PhD from University of California San Diego(UCSD) Biomedical Sciences graduate program and did postdoctoral studies under both academic and pharmaceutical settings. During his post-doctoral studies, he focused on cellular mechanisms regulating stem cells and cancer stem cells through next-gen sequencing data generation, analysis, interpretation and mining. Dev joined QIAGEN as a field application scientist in 2015. In the past 3 years, he has provided trainings to many pharma, biotech, academic and government investigators for different QIAGEN bioinformatics software. In addition, he has helped many of these users troubleshoot problems with their existing workflows and design new workflows.
                          • Chandra Mohan, PhD
                            Senior Manager, Scientific Content and Training, MilliporeSigma
                            Biography
                              Chandra Mohan received his Ph.D. in 1976 from Bangalore University and did his post-doctoral work from 1977 to 1983 at the University of Southern California, School of Medicine. From 1983 to 1993 he was an Assistant Professor of Pharmacology and Nutrition at the University of Southern California, Medical School in Los Angeles. During this time he also served as an Associate Editor of the journal "Biochemical Medicine and Metabolic Biology." In 1993 he joined Calbiochem (EMD), working as the Director of Technical Services & Training and Senior Technical Writer. In 2013, he was appointed Director, Technical Marketing at EMD Millipore and is currently Senior Manager, Scientific Content and Training at MilliporeSigma. Chandra's research interests include diabetes, biochemical basis of stress, inflammation, and the biology of the aging grain. He is a member of the American Society of Biochemistry and Molecular Biology (ASBMB) and the American Association for the Advancement of Science. Dr. Mohan has more than 45 publications in peer reviewed journals and has delivered over 500 seminars to academic and industrial audiences. You can find his bio featured in Who's Who in America, Who's Who in the West, and Who's Who in Health Care and Medicine.
                            • Andrew Ravanelli, PhD
                              Senior R&D Scientist, Genome and Epigenome Editing, MilliporeSigma
                              Biography
                                Andrew has spent more than a decade using genetic manipulation and analysis to dissect molecular mechanisms involved in cell fate specification and behavior in cell culture and in animal models of development and disease. He earned his Ph.D. in Cell Biology from Duke University and completed a postdoctoral fellowship in Pediatrics at the University of Colorado School of Medicine, developing expertise in high-throughput screening, developmental neuroscience, and gene editing. Andrew joined MilliporeSigma in 2016 and has been developing new tools and strategies to modulate gene expression using CRISPR-Cas9.
                              • Samuel Rulli, PhD
                                Senior Global Product Manager, RNA Profiling , QIAGEN
                                Biography
                                  Samuel Rulli is a Senior Global Product Manager for the QIAseq RNA Profiling Technologies at QIAGEN. Dr. Rulli received his Ph.D. in 2002 from Tulane University studying the gastric proton pump and did post-doctoral research at Johns Hopkins University and the National Cancer Institute in Frederick, MD. He joined SABiosciences - now a part of QIAGEN - in 2007 as an R&D Scientist in qPCR applications and moved to a Global Product Manager role in 2014. Trained as a molecular biologist, Dr. Rulli has worked on different assay detection technologies for gene expression and nucleic acid analysis.
                                • Jonathan Shaffer, PhD
                                  Associate Director, NGS Assay Technologies, QIAGEN
                                  Biography
                                    Dr. Shaffer joined QIAGEN in 2009 and has since worked with various technology development groups, the most recent being miRNA technologies. He received his Ph.D. in biochemistry and molecular genetics from the University of Pittsburgh School of Medicine in 2008 where his research focused on determining the mechanisms that regulate non-receptor tyrosine kinase expression and activity. Dr. Shaffer did his postdoctoral training at SABiosciences Corporation, now part of QIAGEN. Currently, Dr. Shaffer is a Senior Scientist in product development at QIAGEN .
                                  • Khyati Shah, PhD
                                    Post Doctoral Research Scholar at University of California, San Francisco
                                    Biography
                                      Khyati Shah received her Ph.D. in Molecular Pharmacology from the University of the Pacific, Stockton, California. Her graduate research was completed in the lab of Jesika Faridi, Ph.D. Her work focused on the investigation of the mechanism of Akt induced tamoxifen resistance in breast cancer. Currently, Khyati is the research fellow in Bandyopadhyay Lab since 2015. Her project involves investigation of the mechanism of resistance to targeted and immuno-therapy using systems biology approach. She has three-first author publications in the reputed peer-reviewed journals and 7 oral and 15 poster talks on the use of systemic genomics and proteomic approach to design rational combination therapy and to increase the durability of therapeutic response.
                                    • Paul Sondel, MD, PhD
                                      Professor of Pediatrics, Department of Human Oncology & Genetics, University of Wisconsin-Madison
                                      Biography
                                        Paul Sondel, M.D., Ph.D. is the Reed and Carolee Walker Professor of Pediatrics, Human Oncology and Genetics and Director of Research for the Division of Pediatric Hematology, Oncology and BMT at the University of Wisconsin - Madison (UW). He has focused on basic, translational and clinical cancer immunotherapy since 1969. Following BS-1971 and Ph.D.- 1975 (UW, mentored by BMT pioneer, Fritz Bach, M.D), M.D.- 1977 (Harvard Medical School) and residencies at U. of Minnesota and UW, he joined the UW faculty in 1980. He was Head of PHO-BMT from 1990 - 2016, and helped lead cancer immunology research at the UW-Carbone-Cancer-Center (UWCCC) since 1990. His laboratory has pursued strategies for enabling immune responses to impact on cancer; some have moved into clinical testing in adults at the UWCCC and in children through the COG. This includes collaborative development of an FDA-approved immunotherapy regimen (dinutuximab+ IL2+ GM-CSF) for children with neuroblastoma. He has held multiple committee/leadership roles, including at The NIH/NCI, American Cancer Society, Children's Oncology Group, and St. Jude's Children's-Research-Hospital. He has been a scholar of the Leukemia Society of America, recently received a 7-year Outstanding Investigator Award from the NCI, and the SITC's Smalley Award for 2017. He has published more than 390 scientific articles and chapters, and trained more than 70 graduate students and post-doctoral fellows in his lab. He also enjoys biking and canoeing; but most of all, he and his wife of 45 years (Sherie) love being parents and grandparents.
                                      • Marina Walther-Antonio, PhD
                                        Associate Consultant, Department of Surgery & Department of Obstetrics & Gynecology, Assistant Professor, Microbiome Program, Center for Individualized Medicine, Mayo Clinic
                                        Biography
                                          Marina Walther-Antonio, PhD is an Associate Consultant in the Department of Surgery and Department of Obstetrics and Gynecology and an Assistant Professor in the Microbiome Program at Mayo Clinic. She leads an interdisciplinary research program that studies the role of the human microbiome in women's health, and in gynecologic cancers in particular. In order to achieve this, Dr. Walther-Antonio and her research team have characterized the female reproductive tract microbiome in benign gynecologic conditions, cancer precursors, and endometrial and ovarian cancer manifestation. Their efforts have resulted in the identification of microbiota markers for endometrial cancer and in the development of translational approaches towards early detection and prevention of the disease. The ultimate goal is to pinpoint intervention opportunities that are amenable to modification of disease risk or can diminish the use of aggressive therapeutic options. Dr. Walther-Antonio's ovarian cancer research is concentrated on the search for an early detection microbiome biomarker and mechanistic role in response to therapy involving monitoring during a clinical trial and patient derived xenograft mouse model. Because mechanistic microbiome studies benefit from complex host/microbe interrogation with a cellular level of resolution, the research team is also focused on the development and application of single-cell microfluidic technologies, such as Optofluidics and Digital Microfluidics.
                                        • Kevin Williams, PhD
                                          Associate Professor, Biomanufacturing Research Institute and Technology Enterprise, NC Central University
                                          Biography
                                            Dr. Kevin P. Williams, Ph.D. is an Associate Professor in the Department of Pharmaceutical Sciences and a faculty member of BRITE at North Carolina Central University. Dr. Williams has over 25 years combined experience in both academic and biopharmaceutical-based research with a focus on cancer and drug discovery. Dr. Williams received his B.Sc. in Biochemistry from the University of Bath in the UK and received his Ph.D. in Biochemistry from the University of Cambridge (UK). He completed his postdoctoral work at Massachusetts General Hospital and the Joslin Diabetes Center in Boston. Prior to joining NCCU in 2007, he spent six years as a Senior Scientist at Biogen in the Department of Protein Engineering and four years at Amphora Corp as Director of Enzyme Drug Discovery. At NCCU he has obtained NIH and DOD research support and mentored 12 Masters level graduate students. His lab currently focuses on identifying novel modulators of the hedgehog pathway. Dr. Williams serves as course director and main instructor for the undergraduate bioprocessing and graduate-level biomanufacturing classes. He is co-author of over 45 publications and co-inventor on 9 patents.
                                          Sponsored By

                                          For information on becoming a sponsor or exhibitor, please click here.


                                          C.E. Credits

                                          The speakers below have been approved for CME, CE, or CEU credits. To redeem your credits, locate the presentation you watched and click on the CME/CE/CEU buttons for further direction. For more general information regarding continuing education, the processes to receive credits, and the accreditation bodies, Click here


                                          Committee

                                          To download the Program Committee brochure here.


                                          • David Albala, MD

                                            Dr. David M. Albala graduated with a geology degree from Lafayette College in Easton, Pennsylvania. He completed his medical school training at Michigan State University and went on to complete his surgical residency at the Dartmouth-Hitchcock Medical Center. Following this, Dr ...

                                            See more See less
                                          • Sharon Geaghan, MD

                                            Dr. Geaghan is Chief, Pathology at Lucile Packard Children's Hospital at Stanford, and Co-Director of Clinical Laboratories at Stanford Hospital and Clinics. She also directs the Bass Pediatric Cancer Center Laboratory at the Lucile Packard Hospital; is Director of the Point of ...

                                            See more See less
                                          • Josip Blonder, MD

                                            Dr. Blonder leads the Clinical Proteomics Group at the CRTP/FNL. FNL is a Federally Funded Research and Development Center operated by Leidos Biomedical Research, Inc., for the National Cancer Institute (NCI). In 1978, Dr. Blonder received his M.D. at the Rijeka University ...

                                            See more See less
                                          • Peter Blume-Jensen, MD, PhD

                                            Dr. Peter Blume-Jensen has extensive expertise in basic and translational cancer research, oncogenic signaling, and targeted oncology therapeutics drug discovery prior to joining Metamark as CSO in 2010.  From 2001 to 2008 Peter was department head at first Serono, US and ...

                                            See more See less
                                          • Fred Russell Kramer, PhD

                                            Fred Russell Kramer currently works at the Department of Microbiology, Biochemistry and Molecular Genetics, at the Public Health Research Institute of the New Jersey Medical School at Rutgers University. His laboratory's current current project is the design of extremely ...

                                            See more See less
                                          • Martin Latterich, PhD

                                            The discovery of proteinaceous disease biomarkers and their clinical validation is critically important for the enablement of molecular diagnostics and ultimately, precision medicine. In spite of the importance of biomarkers, research done in the last two decades has yielded ...

                                            See more See less
                                          • Ariel Louwrier PhD

                                            Successful Senior Scientific Business Executive with demonstrated expertise growing markets, revenues, product pipelines and expanding technical organizations into new business opportunities. Educational and business management experience in global markets, with quantified ...

                                            See more See less
                                          • Judd Moul, MD, FACS

                                            Judd W. Moul is James H. Semans, MD Professor of Surgery, Division of Urologic Surgery, and Director of the Duke Prostate Center, Duke Cancer Institute at Duke University Medical Center. Prior to joining Duke, he was Professor of Surgery at the Uniformed Services University of ...

                                            See more See less
                                          • Thomas Polascik, MD

                                            Thomas J. Polascik, M.D. is Professor in the Duke Cancer Institute, the Department of Surgery at the Duke University Medical Center, Durham, NC. Dr. Polascik trained at the Brady Urological Institute, the Johns Hopkins Hospital in Baltimore Maryland. After finishing his residency ...

                                            See more See less
                                          • Rajan Gupta, MD

                                            Dr. Rajan T. Gupta, MD, is an Assistant Professor of Radiology in the Division of Abdominal Imaging at Duke University Medical Center, as well as the Director of the Abdominal Imaging Fellowship Program and a Faculty physician in the Duke Cancer Institute. Since 2009, he has been ...

                                            See more See less
                                          • Antonio Baines, PhD

                                            Dr. Antonio T. Baines is an Associate Professor in the Department of Biology at North Carolina Central University (NCCU) and an adjunct professor in the Department of Pharmacology in the School of Medicine at the University of North Carolina (UNC) Chapel Hill. He earned a ...

                                            See more See less
                                          • Louise Perkins, PhD

                                            Dr. Perkins joined the Melanoma Research Alliance as Chief Science Officer in 2013 where she is responsible for the development and implementation of the MRA's scientific strategy including its research award program and annual Scientific Retreat. Her interests center on ...

                                            See more See less
                                          • Martin Latterich, PhD

                                            The discovery of proteinaceous disease biomarkers and their clinical validation is critically important for the enablement of molecular diagnostics and ultimately, precision medicine. In spite of the importance of biomarkers, research done in the last two decades has yielded ...

                                            See more See less
                                          Help

                                          General LabRoots Questions

                                          For bugs, spam, technical support or questions please call +1-714-463-4673 or email support@labroots.com  
                                          Contact us

                                          Virtual Events and Webinars

                                          Supported Configurations

                                          • Operating System Internet Explorer Firefox Chrome Safari
                                            Vista IE8+ FF10+ Chrome15+
                                            Windows 7 IE8+ FF10+ Chrome15+
                                            Windows 8 IE10 FF10+ Chrome15+
                                            Mac OS X   FF10+ Chrome15+ Safari5.1+
                                          • Cookie settings: session cookies enabled
                                          • Browser configuration must have JavaScript enabled
                                          • Adobe Flash player 10.2 or later

                                          To watch our webinars and virtual events a modern browser such as Chrome, Firefox, Safari, or an updated version of Internet Explorer is required.

                                          Internet Connection

                                          • A minimum of 100Kbps is recommended for audio-only events
                                          • A minimum of 300Kbps is recommended for speaker on-video events

                                          Computer Equipment

                                          • Screen Resolution: Minimum 1024x768
                                          • Video Card: 65,000 colors minimum
                                          • Sound card and speakers (or headphones) for hearing webcast in full format
                                          • Audio Card: 16-bit minimum
                                          • RAM: 512MB of free RAM

                                          Firewall Protocol

                                          • HTTP on port 80 or HTTPS on port 443
                                          • Adobe RTMP on port 1935, 80, or 443 with automatic fall-back to RTMPT (RTMP tunneling) on ports 1935, 80 or 443
                                          • RTMPE (RTMP encrypted) on ports 1935, 80 or 443

                                          Work-At-Home Attendees

                                          • If a corporate VPN is used, confirm that your network traffic is not directed over the company VPN. If it is, please turn off the VPN while attending the virtual event.

                                          For A Seamless Experience

                                          When using a mobile device, FREE Mobile Apps are available:

                                          - For viewing Webinars:

                                          - For viewing Virtual Events

                                          Attendee Guide

                                          • To learn more about how the virtual event works for attendees, download the Attendee Guide (PDF).

                                          Virtual Event and Webinar Support:

                                          Continuing Education (CME/CE) Support

                                          Loading Comments...
                                          Show Resources